By Jennifer Ahlstrom | Posted - Jul 13th, 2018

 

 

 

 

CAR T Dosing and Enrollment Increase Changes Made in Celgene/Bluebird KarMMa Study

Celgene has amended the protocol of the Phase II KarMMa study to increase the dose and number of patients to be enrolled for the CAR T bb2121 treatment. The study is currently open for relapsed/refractory multiple myeloma. 

Based on prior data, the dose in the Phase II study has been increased to 15 - 45 x 10CAR T-cells from 15 - 30 x 10cells. The study will enroll up to 140 patients.  

The Phase I study (called CRB-401) will also increase enrollment to an additional 20 patients and the dose range will be the same as the KarMMa study. 

Celgene and bluebird bio anticipate regulatory approval for bb2121 for multiple myeloma in 2020. 

 

 
Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Jenny A - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio, HealthTree and the CrowdCare Foundation.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

Add a Comment

 

MORE MYELOMA CROWD NEWS

Thanks to our site sponsors:

.